10173524PHARMORIS™ - Generics Optimisation Platform for NHS and Global HealthClosedFast Start ResponseInnovate UKPHARMORIS® is a digital platform being developed by NEUVIOR Pharmaceuticals Ltd, a UK incorporated, pharmaceutical and technology company, focused on improving access and resilience across healthcare systems. Founded by 25 year old, neurodivergent, British entrepreneur, Varun Cruz; NEUVIOR develops pharmaceutical supply intelligence and digital regulatory systems to support more efficient delivery of medicines in the UK and internationally. This project focuses specifically on the development of PHARMORIS, the company’s first commercial platform. PHARMORIS is an AI enabled decision support platform designed to improve how generic medicines are identified and progressed through regulatory pathways for the NHS and wider health systems. The platform applies deep tech to structured data models and analytical methods, to support more efficient preparation and management of regulatory submissions, including electronic Common Technical Document (eCTD) workflows, informed by patent landscape, pricing, and supply intelligence. The NHS spends over £17 billion per year on medicines, with generic medicines accounting for approximately 75% of all prescriptions. Despite this, delays between patent expiry and NHS adoption of generics often range from 6 to 12 months, and more than 150 medicines experienced supply shortages in 2024. These delays and disruptions create avoidable costs and limit timely patient access to essential treatments. PHARMORIS addresses these challenges by bringing together NHS prescribing data, medicine pricing, patent timelines, and regulatory information into a single integrated platform. This enables earlier identification of priority medicines, clearer regulatory pathways, and more coordinated planning across stakeholders involved in generic medicine supply. This replaces manual, fragmented regulatory and supply workflows with an integrated, data driven decision support process. The platform is being developed with a strong emphasis on governance, auditability, and regulatory compliance, with the aim of supporting faster, more resilient access to generic medicines whilst aligning with NHS procurement and supply chain requirements. By April 2026, the project will deliver a working prototype capable of identifying high priority generic medicines, streamlining e-CTD regulatory workflows, and supporting improved supply resilience across the UK pharmaceutical system. The project contributes to UK priorities in pharmaceutical innovation, digital transformation, cost efficiency, and healthcare system resilience, and aims to provide a blueprint for a more sustainable national medicines infrastructure.